Anavex Life Sciences Corp (AVXL)

[BAR123]

The biggest issue I have with AVXL is that it has never received the respect it deserves. We saw one brief rise to $31 with no news, but despite having the best data in the industry, the stock didn’t move much. Every other CNS company that released decent news saw huge run-ups—every single one. Yes, they all eventually pulled back, but we never got that spike. Remember, even with the best data ever, no run. Why?

My theory is that Dr. Missling needs to be elevated to CEO, and a new president should be brought in. Why do you think we never got the run we deserve? Think back to when BIIB surged by $20 billion in market cap—we should have at least hit a $4 billion market cap. SAVA shot up to $120 per share, ANVS to $132, and AXSM to $130. Why not AVXL?

Who has the answer to this? I could accept a rise to $30 followed by a pullback to $20, but sitting here at $7.97 is crazy. Unless, of course, we’re not being believed, or maybe we’re being accumulated and the games are being played until we approach key milestones, like the first stop for Q&A, approval, or a partnership.

I understand that a buyback will never happen, and the executives won’t be purchasing shares—they never do. After most of them being on board for 5-10 years they have collected enough free shares. Just buy a little. All of them. But share purchases would signal to everyone that the company is in great shape and encourage patience. What do you think is behind the lack of a run-up for AVXL? Trust of Missling? Trouble with the data? No FDA love over the years?

Thanks in advance.